• What if law firms advertising about drugs had to live with the same set of rules as drug firms advertising about drugs? [Beck, Drug and Device Law]
• Jury: no injury damages for testosterone-gel plaintiff, but lawyer got us upset at AbbVie so here’s $150 million anyway [Lisa Schencker, Chicago Tribune]
• “Plaintiff’s design defect claim was that the defendant shouldn’t have used ibuprofen at all, but rather [an alternative compound] even though the FDA has not approved [that compound] for sale in the United States.” That won’t fly even in California [Beck]
• Sky-high prices: “The pharmaceutical market is anything but free at present” [Marc Joffe, Reason]
• Opioids epidemic poses a policy challenge but no time to panic [Jeffrey Singer/Cato, related podcast, op-ed, panel; an ACA angle?]
• “Gene editing isn’t about designer babies, it’s about hope for people like me” [Alex Lee, Guardian]

Filed under: chasing clients, FDA, illegal drugs, opioids, pharmaceuticals, product liability